Biogen To Seek Re-examination Of Negative Opinion By EMA For Its 'aducanumab'
17/12 13:38
(RTTNews) - Biogen Inc. (BIIB), an American company focused on the therapies for the treatment of neurological diseases said it intends to seek re-examination of negative opinion adopted by European Medicines Agency or EMA for the company's Alzheimer's drug aducanumab....